Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

NCT02034708 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Brain Tumor

Interventions

DRUG: Dotarem®
DRUG: Gadovist®/Gadavist®

Sponsor

Guerbet